88 research outputs found
Facial segmental lipoatrophy effectively treated with a deep priming filler incorporating calcium hydroxyapatite with results sustained for 12 months
Facial segmental lipoatrophy poses a cosmetic challenge for which various interventions have been explored. This study reports the successful treatment of facial segmental lipoatrophy using a deep priming filler formulation containing calcium hydroxyapatite. The treatment demonstrated effectiveness in restoring facial volume, with notable results sustained over a 12-month period. The incorporation of calcium hydroxyapatite in the filler formulation contributed to enhanced longevity and stability of outcomes. This promising approach represents a valuable option for addressing facial segmental lipoatrophy, offering a long-lasting solution with potential implications for cosmetic dermatology practices. Further research and clinical studies are warranted to validate and extend these findings
Efficacy of Cemiplimab in a patient affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
Cutaneous squamous cell carcinoma (cSCC) is a prevalent skin malignancy, often managed through surgical intervention. However, in certain cases, especially when complicated by concurrent hematologic disorders such as myelodysplastic syndrome (MDS), treatment options become more challenging. This abstract highlights a case study examining the efficacy of cemiplimab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), in a patient diagnosed with both cSCC and MDS.
The patient, initially presenting with an advanced cSCC lesion and underlying MDS, underwent treatment with cemiplimab as a therapeutic approach. Monitoring of the patient's response included clinical evaluation, radiological assessments, and laboratory analyses. Results demonstrated a notable reduction in the size of the cSCC lesion and stabilization of hematologic parameters, suggesting a positive therapeutic effect of cemiplimab in this complex clinical scenario.
This case underscores the potential utility of immunotherapeutic agents, specifically PD-1 inhibitors like cemiplimab, in the management of cutaneous malignancies coexisting with hematologic disorders. Further investigations and larger-scale studies are warranted to validate these findings and establish cemiplimab's role as a viable treatment option in similar clinical contexts
Gender matter in isotretinoin therapy for acne vulgaris? A retrospective study
Introduction: Gender differences have been recently highlighted for several aspects of acne vulgaris such as epidemiology, pathogenesis, clinical course, quality of life and treatment outcome. In particular a shorter but more severe clinical course has been reported in males than in females; nevertheless, usually men have their quality of life less affected.
Aim: To determine if the response and the adverse events to 1 cycle of oral isotretinoin therapy can be influenced by gender.
Methods: A retrospective study was conducted on consecutive patients affected by acne vulgaris and treated with oral isotretinoin. Global acne grading system (GAGS), acne-related quality of life (AQoL) and isotretinoin-related adverse events were considered as outcome measures and were evaluated before (T0), every month during administration and 4 weeks after the withdrawal (T1) of oral isotretinoin therapy. Mann-Whitney U test and Wilcoxon signed-rank test were used for quantitative parameters and Fisher exact test for qualitative ones.
Results: Forty-nine acneic patients were retrospectively selected (33 males 67.3% and 16 females -32.7%; median age: 19 years). Patients had received a median dosage of isotretinoin of 0.4 mg/kg/die for a median period of 5 months; no differences in outcome measures among genders were reported.
Limitations: The study is retrospective and the sample is small and not homogenously distributed among genders, as males are double in number than females.
Conclusions: In our study population gender didn't influence neither the clinical and the quality of life outcome measures nor the occurrence of adverse events to oral isotretinoin therapy for acne
Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
AIM
To determine factors independently influencing response to ingenol mebutate therapy and assess efficacy on clinical setting of non-hypertrophic non-hyperkeratotic actinic keratosis (AK).
METHODS
Consecutive patients affected by non-hypertrophic non-hyperkeratotic AKs of the face or scalp were enrolled to receive ingenol mebutate 0.015% gel on a selected skin area of 25 cm2 for 3 consecutive days. Local skin reactions were calculated at each follow up visit using a validated composite score. Efficacy was evaluated by the comparison of clinical and dermoscopic pictures before the treatment and at day 57, and classified as complete, partial and poor response.
RESULTS
A number of 130 patients were enrolled, of which 101 (77.7%) were treated on the face, while 29 (22.3%) on the scalp. The great majority of our study population (n = 119, 91.5%) reached at least a 75% clearance of AKs and, in particular, 58 patients (44.6%) achieved a complete response while 61 (46.9%) a partial one. Logistic backward multivariate analysis showed that facial localization, level of local skin reaction (LSR) at day 2, the highest LSR values and level of crusts at day 8 were factors independently associated with the achievement of a complete response.
CONCLUSION
Ingenol mebutate 0.015% gel, when properly applied, is more effective on the face than on the scalp and efficacy is directly associated to LSR score
Management of psoriatic patients in biologic treatment associated with infectious comorbidities
Introduction: Psoriasis is a chronic inflammatory disease affecting about 2% of population, involving both acquired and innate immunity. Psoriasis affects mainly skin, presenting multiple co-morbidities; among them infective ones. Re-activation of tuberculosis or viral hepatitis (HBV and HCV) still represents a therapeutic challenge in patients receiving treatment with biological drugs, as well as HIV infection. For this reason, a multidisciplinary approach with global treatment resulting from active collaboration of different specialists is highly recommended.Aim: To investigate the most common infective diseases as co-morbidities associated with psoriasis and to provide algorithms for screening, follow-up and therapeutic management in psoriatic patients.Material and methods: We examined the main infectious comorbidities that can affect moderate to severe psoriatic patients, influencing the therapeutic choice as during the biological treatment both viral and tuberculosis re-activation may occur. We have therefore evaluated the main diseases (TB, Hepatitis B and C, HIV) and the monitoring of patients during treatment with biological agents.Results: Regular monitoring of psoriatic patients is recommended during long-term treatment with biological drugs in order to identify cases of re-activation of the latent infective agent or de novo acquired infection.Conclusions: Here we report the state of art regarding management of psoriatic patients with these co-morbidities suggesting a specific screening and management for infectious diseases in patients with moderate to severe plaque psoriasis
Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series
Erythrodermic psoriasis (EP) is a very rare but extremely
severe subtype of chronic plaque psoriasis,
affecting 1.00-2.25% of patients with psoriasis (1).
Its pathogenesis still remains unknown, and current
therapeutic strategies frequently end in failure. In this
condition, the skin becomes diffusely red, tending to
purple, shiny, with marked desquamation and exudation.
Erythema and edema are widespread, covering
more than 90% of the body surface and can lead to
high risk of multi-organ failure and death (2) due to
fluid and protein loss.
Predominance of the Th2 immune response and
dysregulation of angiogenesis have been proposed
to be implicated in the pathogenesis of EP, although
this has not yet been fully elucidated (3).
Nevertheless, Th17 has been shown to be the
second-most predominant T-cell type after Th2 in EP
lesions (4,5)
Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series
Erythrodermic psoriasis (EP) is a very rare but extremely
severe subtype of chronic plaque psoriasis,
affecting 1.00-2.25% of patients with psoriasis (1).
Its pathogenesis still remains unknown, and current
therapeutic strategies frequently end in failure. In this
condition, the skin becomes diffusely red, tending to
purple, shiny, with marked desquamation and exudation.
Erythema and edema are widespread, covering
more than 90% of the body surface and can lead to
high risk of multi-organ failure and death (2) due to
fluid and protein loss.
Predominance of the Th2 immune response and
dysregulation of angiogenesis have been proposed
to be implicated in the pathogenesis of EP, although
this has not yet been fully elucidated (3).
Nevertheless, Th17 has been shown to be the
second-most predominant T-cell type after Th2 in EP
lesions (4,5)
Aesthetic treatments in cancer patients
Cancer patients are experiencing an increase in overall survival as a consequence of earlier diagnosis and newer effective anticancer therapies. However, cancer survivors often face long-term consequences from their original cancer diagnosis and long-term sequelae of anticancer treatment. Maintaining patients' quality of life is of paramount importance and this can be accomplished by a multidisciplinary treatment approach, including aesthetic treatments to improve patients' body image and positively impact their quality of life. In this perspective, we will discuss the importance of aesthetic treatments in cancer patients. In addition, we will summarise the data available regarding the use of several aesthetic treatments such as fillers, botulinum toxin and laser use in cancer patients, their safety, their efficacy, and the specific precautions that need to be implemented in this particular subset of cancer patients
Herpes zoster ophthalmicus in two women after Pfizer-BioNTech (BNT162b2) vaccine
Varicellaâzostervirus(VZV) isresponsibleforaprimaryinfection (i.e., chickenpox); subsequently, thevirus remains dormant at the level of thespinal dorsal root andcranial ganglia. Inconditionsof stressor immunosuppression, itcanreactivateandcausesecondary herpes zoster (HZ) infection. HZOaccounts for 10%â20%ofHZ casesandischaracterizedbyinvolvementoftheophthalmicbranch ofthefifthcranialnerve. It isconsideredadangerousconditionthat couldleadtosevereconsequencessuchasblindnessin20%â70%of thecases.3Themainriskfactors for thereactivationofVZVarea compromiseofthecellâmediatedimmunity(CMI)thatpresentsitself inoldage, insomechronicdiseasessuchasdiabetes, autoimmune disease,HIV,andduringimmunosuppressivetherapies.4 Several casesofHZhavebeendescribed inPfizervaccinerecipients,however,onlyoneofthemwithophthalmiclocalization, ina 56âyearâoldwomanwithrheumatoidarthritis.5 Wereport twocasesofpostvaccineHZOalthoughararelyreportedadverseeventwithpotentiallyseriousconsequences. HZOwasalsodiagnosedinfourpatientssufferingfromamoderateformofCOVIDâ19infection6thatwereeffectivelytreatedwith antiviralswithoutanyvisual sequelae. Inthesecases, thetriggering factorforviralreactivationisprobablyduetolymphopeniasecondary to SARSâCoVâ2
- âŠ